The Village of Oak Park | 123 Madison St.  Oak Park, IL 60302 |

Main menu


Symptomatic, lab-diagnosed patients urged to ask about specific treatment

With FDA approval of an emergency use authorization for the laboratory-made proteins called monoclonal antibodies to treat COVID-19, Interim Oak Park Public Health Director Joseph Terry is urging patients who have been diagnosed positive to be proactive and ask their doctors to consider the treatment.

The combination of the proteins casirivimab and imdevimab are administered intravenously to treat mild to moderate COVID-19 in patients 12 years of age or older weighing at least 88 pounds.

Terry said testing also has shown the combination to be effective in treating those at higher risk for progressing to severe COVID-19, including individuals 65 and older or who have certain chronic medical conditions. The treatment should be available throughout Illinois, he said. 

Click here to read more about the treatment.

More information about the Village's COVID-19 response is at